La chaîne d'options affiche les données clés des options sur actions de Cullinan Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Cullinan Therapeutics..

Cullinan Therapeutics (NASDAQ:CGEM) Stock, Chaîne d'Options

Cullinan Therapeutics

Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics Inc

Capgemini SE

For the full year 2025, the Company expects GAAP revenue of approximately $1.0 billion, representing revenue growth of approximately 5% year-over-year. The Company expects Adjusted Gross Profit Margin to be in the range of 47.0% to 47.5%. The Company expects Adjusted EBITDA to be in the range of $225 million to $235 million and Adjusted Diluted EPS to be in the range of $3.35 to $3.55. The Company's guidance assumes no significant changes in foreign exchange rates.
 &nbsp;

News

Guidance

NOVT

Novanta Expects FY25 Revenue Of ~$1B Vs $1.04B Est, Adj EPS Of $3.35-$3.55 Vs $3.79 Est

Dividends

Stantec's Board Approves 7% Increase In Dividend To $0.22

Legal

CDNA

CareDx Announces District Court Overturned Jury Verdict In Patent Litigation, Overturning Prior $96 Million Verdict

Bowhead Specialty Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOW#NYSE">BOW</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.33 by 27.27 percent. This is a 75 percent increase over earnings of $0.24 per share from the same period last year. The company reported quarterly sales of $119.33 million which beat the analyst consensus estimate of $101.43 million by 17.65 percent. This is a 44.11 percent increase over sales of $82.81 million the same period last year.

Earnings

Earnings Beats

Bowhead Specialty Holding Q4 Adj EPS $0.42 Beats $0.33 Estimate, Sales $119.33M Beat $101.43M Estimate

Mizuho analyst Ben Chaiken maintains Marriott Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) with a Outperform and raises the price target from $117 to $120.

Price Target

Analyst Ratings

Mizuho Maintains Outperform on Marriott Vacations, Raises Price Target to $120

GTBP

GT Biopharma  Files Request For Withdrawal With SEC  With Respect To Withdrawal Of Form S-1 Registration Statement, Filed On Dec. 23

Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 700 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $148.546 million which beat the analyst consensus estimate of $146.380 million by 1.48 percent. This is a 15.92 percent increase over sales of $128.145 million the same period last year.

XMTR

Xometry Q4 2024 Adj. EPS $0.06 Beats $0.03 Estimate, Sales $148.546M Beat $146.380M Estimate

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Buy and maintains $15 price target.

Reiteration

TBPH

HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $15 Price Target

Citigroup analyst Asiya Merchant maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Buy and raises the price target from $60.45 to $64.

Citigroup Maintains Buy on Western Digital, Raises Price Target to $64

Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.32) by 3.13 percent. This is a 22.5 percent increase over losses of $(0.40) per share from the same period last year.

FULC

Fulcrum Therapeutics Q4 GAAP EPS $(0.31) Beats $(0.32) Estimate

DOCN

DigitalOcean Holdings Q4 2024 Adj. EPS $0.49 Beats $0.34 Estimate, Sales $204.925M Beat $200.507M Estimate

Stantec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STN#NYSE">STN</a>) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.69 by 14.49 percent. This is a 31.67 percent increase over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $1.06 billion which beat the analyst consensus estimate of $1.01 billion by 4.65 percent. This is a 15.81 percent increase over sales of $912.70 million the same period last year.

Stantec Q4 Adj $0.79 Beats $0.69 Estimate, Sales $1.06B Beat $1.01B Estimate

Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.15 by 6.67 percent. This is a 75 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $1.02 billion which beat the analyst consensus estimate of $1.01 billion by 0.98 percent. This is a 1.45 percent decrease over sales of $1.03 billion the same period last year.

ELAN

Elanco Animal Health Q4 2024 Adj EPS $0.14 Misses $0.15 Estimate, Sales $1.02B Beat $1.01B Estimate

WIIM

RDHL

RedHill shares are trading higher after the company announced an exclusive licensing agreement with Hyloris Pharmaceuticals for RHB-102, including an upfront payment and up to $60 million in potential milestones.

<ul>
<li>Food Processing to be a Fast-Growing and Nimble Standalone Business with Best-in-Class Technologies for Industrial Protein, Bakery, and Snack Processors</li>
<li>Middleby RemainCo Well-Positioned to Drive Sustainable Growth and Margin Expansion Through Innovation Leadership and Differentiated Go-To-Market Capabilities in Commercial Foodservice and Residential Kitchens</li>
<li>Separation of Food Processing Expected to be Achieved Through Tax-Free Spin-Off and be Completed Early 2026</li>
<li>Company Separately Announces Q4 and Full-Year 2024 Financial Results and Appointment of Independent Directors to its Board</li>
</ul>

MIDD

Middleby To Spin Off Food Processing Unit, Forming Independent Food Processing And Kitchen Equipment Leaders

RedHill Enters Exclusive Development And Commercialization Licensing Agreement With Hyloris Pharmaceuticals For RHB-102; Hyloris Will Pay Co. Upfront Payment And Up To $60M In Potential Milestones

For the full year 2025, the Company expects GAAP revenue of approximately $1.0 billion, representing revenue growth of approximately 5% year-over-year. The Company expects Adjusted Gross Profit Margin to be in the range of 47.0% to 47.5%. The Company expects Adjusted EBITDA to be in the range of $225 million to $235 million and Adjusted Diluted EPS to be in the range of $3.35 to $3.55. The Company's guidance assumes no significant changes in foreign exchange rates.
For the first quarter of 2025, the Company expects GAAP revenue of approximately $232 million to $236 million. The Company expects Adjusted Gross Profit Margin to be in the range of 46.0% to 46.5%. The Company expects Adjusted EBITDA to be in the range of $48 million to $51 million and Adjusted Diluted EPS to be in the range of $0.63 to $0.71. The Company's guidance assumes no significant changes in foreign exchange rates.

Novanta Expects Q1 Revenue Of $232M-$236M Vs $244.89M Est, Adj EPS Of $0.63-$0.71 Vs $0.78 Est

AdaptHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.27 by 25.93 percent. The company reported quarterly sales of $856.65 million which beat the analyst consensus estimate of $829.19 million by 3.31 percent. This is a 0.18 percent decrease over sales of $858.23 million the same period last year.

AHCO

AdaptHealth Q4 2024 GAAP EPS $0.34 Beats $0.27 Estimate, Sales $856.65M Beat $829.19M Estimate

Delek US Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DK#NYSE">DK</a>) reported quarterly losses of $(2.54) per share which beat the analyst consensus estimate of $(2.81) by 9.61 percent. This is a 73.97 percent decrease over losses of $(1.46) per share from the same period last year. The company reported quarterly sales of $2.37 billion which missed the analyst consensus estimate of $2.58 billion by 7.84 percent. This is a 41.38 percent decrease over sales of $4.05 billion the same period last year.

Earnings Misses

Delek US Hldgs Q4 2024 Adj EPS $(2.54) Beats $(2.81) Estimate, Sales $2.37B Miss $2.58B Estimate

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) sees FY2025 sales of $818.000 million-$826.000 million vs $847.01 million analyst estimate.

OFIX

Orthofix Medical Sees FY2025 Sales $818.000M-$826.000M vs $847.01M Est

Press Releases

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Health Care

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Clear Street Launches Healthcare & Biotechnology Equity Research

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

Comments

Cullinan Therapeutics

Cullinan Therapeutics (CGEM) Options

Cullinan Therapeutics (NASDAQ:CGEM) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL